Craft

Medicenna Therapeutics

Stock Price

$1.4

2024-03-28

Market Capitalization

$96.2 M

2024-03-28

Medicenna Therapeutics Summary

Company Summary

Overview
Medicenna Therapeutics is an immunotherapy company focused on oncology. It develops and commercializes selective versions of IL-2, IL-4, and IL-13 Superkines and Empowered Cytokines (ECs) for the treatment of a range of cancers. The company offers a technology platform that delivers potent cell-killing agents for cancer as well as actively alters the immunosuppressive tumor micro-environment without harming healthy cells.
Type
Public
Status
Active
Founded
2012
Website
https://www.medicenna.com
Cybersecurity rating
Sectors

Key People

  • Rosemina Merchant, Chief Development Officer and Director

  • Chandra Panchal, Director

    • Fahar Merchant

      Fahar Merchant, President, Chief Executive Officer, Director

    • Albert G. Beraldo, Director

      Medicenna Therapeutics Financials

      Summary Financials

      Net income (Q3, 2024)
      ($C5.0M)
      Cash (Q2, 2024)
      $C25.7M
      EBIT (Q3, 2024)
      ($C4.8M)
      Enterprise value
      $61.0M

      Footer menu